Argentarii LLC bought a new stake in Stryker Co. (NYSE:SYK - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 681 shares of the medical technology company's stock, valued at approximately $245,000.
Other large investors have also modified their holdings of the company. Kohmann Bosshard Financial Services LLC acquired a new stake in Stryker during the fourth quarter valued at approximately $25,000. Dunhill Financial LLC raised its position in shares of Stryker by 94.9% during the 3rd quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company's stock valued at $27,000 after acquiring an additional 37 shares in the last quarter. Centricity Wealth Management LLC bought a new position in Stryker during the fourth quarter worth $30,000. BankPlus Trust Department acquired a new position in Stryker in the fourth quarter worth $33,000. Finally, Darwin Wealth Management LLC bought a new stake in Stryker during the third quarter valued at $36,000. Institutional investors own 77.09% of the company's stock.
Stryker Stock Down 0.5 %
Shares of SYK traded down $1.77 during midday trading on Wednesday, reaching $363.52. 1,559,119 shares of the stock were exchanged, compared to its average volume of 1,218,441. The company has a market cap of $138.71 billion, a price-to-earnings ratio of 46.85, a P/E/G ratio of 2.93 and a beta of 0.95. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59. Stryker Co. has a 12-month low of $314.93 and a 12-month high of $406.19. The firm has a 50 day simple moving average of $382.76 and a 200-day simple moving average of $373.33.
Stryker (NYSE:SYK - Get Free Report) last issued its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, beating the consensus estimate of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same quarter last year, the firm earned $3.46 EPS. Research analysts forecast that Stryker Co. will post 13.47 EPS for the current year.
Stryker Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be paid a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.92%. The ex-dividend date is Monday, March 31st. Stryker's payout ratio is 43.30%.
Wall Street Analyst Weigh In
A number of research firms have recently issued reports on SYK. The Goldman Sachs Group set a $422.00 price target on shares of Stryker in a research report on Tuesday, March 4th. JPMorgan Chase & Co. raised their target price on shares of Stryker from $420.00 to $445.00 and gave the stock an "overweight" rating in a report on Wednesday, January 29th. JMP Securities restated a "market perform" rating on shares of Stryker in a research note on Tuesday, February 18th. Barclays increased their price target on Stryker from $418.00 to $443.00 and gave the stock an "overweight" rating in a research report on Monday, February 10th. Finally, Morgan Stanley upgraded Stryker from an "equal weight" rating to an "overweight" rating and boosted their price objective for the company from $370.00 to $445.00 in a research report on Monday, December 2nd. Five research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $421.90.
View Our Latest Research Report on SYK
Insider Buying and Selling
In other news, Director Allan C. Golston sold 2,458 shares of the stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total value of $941,586.06. Following the completion of the sale, the director now directly owns 14,895 shares of the company's stock, valued at approximately $5,705,827.65. This represents a 14.16 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Ronda E. Stryker sold 201,392 shares of the business's stock in a transaction on Friday, January 31st. The stock was sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the transaction, the director now directly owns 3,642,075 shares in the company, valued at $1,428,567,498. This trade represents a 5.24 % decrease in their position. The disclosure for this sale can be found here. 5.90% of the stock is owned by insiders.
About Stryker
(
Free Report)
Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.
Further Reading
Before you consider Stryker, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Stryker wasn't on the list.
While Stryker currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
